Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,055 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Hoffmann-La Roche Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

NCT00002377
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
15
States / cities
Irvine, California • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed No phase listed Observational

An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)

NCT01338545
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

NCT02541604
View directory record Official record
Conditions
Solid Tumor
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

VEAPS: Vitamin E Atherosclerosis Prevention Study

NCT00114387
View directory record Official record
Conditions
Atherosclerosis
Interventions
DL-alpha-tocopherol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
40 Years and older
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

NCT00382798
View directory record Official record
Conditions
Healthy Volunteers, Hepatitis C Virus
Interventions
RO5024048
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2009 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

NCT03761849
View directory record Official record
Conditions
Huntingtons Disease
Interventions
RO7234292, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

A Study of RO5045337 in Patients With Solid Tumors

NCT01164033
View directory record Official record
Conditions
Neoplasms
Interventions
RO5045337
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Kensignton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

NCT04285567
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Obinutuzumab, Venetoclax, Fludarabine, Cyclophosphamide, Rituximab, Bendamustine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

NCT00755287
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
insulin glargine, metformin, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

NCT02145234
View directory record Official record
Conditions
Healthy Adults
Interventions
BMS-986089, Placebo matching with BMS-986089
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

NCT02004106
View directory record Official record
Conditions
Neoplasms
Interventions
RO6895882
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

NCT01376804
View directory record Official record
Conditions
Kidney Transplantation, Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
4 Months to 16 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Gainesville, Florida • Los Angeles, Louisiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

The Effect Of Oral Ibandronate In Male Osteoporosis

NCT00397839
View directory record Official record
Conditions
Male Osteoporosis
Interventions
Ibandronate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
30 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2009 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

NCT01667419
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • California City, California • Hayward, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Results available

A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

NCT00711191
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
monoclonal antibody, chemotherapy
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Jul 23, 2026, 2:10 PM EDT
Not listed No phase listed Observational

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

NCT05773196
View directory record Official record
Conditions
Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
Interventions
Biospecimen Collection
Other
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

NCT02624986
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Idasanutlin, Obinutuzumab, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Phoenix, Arizona • Aurora, Colorado • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

NCT01264380
View directory record Official record
Conditions
Malignant Melanoma
Interventions
RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

NCT00099203
View directory record Official record
Conditions
Pain, Bone Neoplasm, Neoplasm Metastasis
Interventions
ibandronate [Bondronat], zoledronic acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
26
States / cities
Birmingham, Alabama • Sedona, Arizona • Ocoee, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy

NCT00106522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed No phase listed Observational

CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients

NCT00227045
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Results available

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

NCT00121836
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
57
States / cities
Birmingham, Alabama • Burbank, California • Glendale, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Jul 23, 2026, 2:10 PM EDT